Trial Profile
A study of anaphylaxis and serum sickness occurrence in patients receiving Omalizumab in a tertiary allergy and asthma clinic in Canada
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Mar 2018
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Asthma; Hypersensitivity; Mastocytosis; Nasal polyps; Nephritis; Seasonal allergic rhinitis; Urticaria
- Focus Adverse reactions
- 23 Mar 2018 New trial record
- 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology